Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01827930 | Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response(MIM) | terminated | Phase 3 | 68 | Institut BergoniéOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT00452439 | A Study of Actonel for the Prevention of Bone Loss | completed | Phase 3 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | completed | Phase 3 | 624 | Children's Oncology GroupNETWORK | 2 | Dec 7, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02381379 | Malaysia Stop Tyrosine Kinase Inhibitor Trial(MSIT) | unknown | Phase 3 | 118 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00137111 | Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | completed | Phase 3 | 501 | St. Jude Children's Research HospitalOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00006083 | Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter | completed | Phase 3 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00070382 | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT00750009 | Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial | completed | Phase 3 | 583 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia(OBERON) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 9, 2020 | clinicaltrials |
| NCT03593304 | Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients | completed | Phase 2 / Phase 3 | 40 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts(ONTIME) | completed | Phase 3 | 299 | Traws Pharma, Inc.INDUSTRY | 6 | Jun 30, 2020 | clinicaltrials |
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | completed | Phase 3 | 67 | Traws Pharma, Inc.INDUSTRY | 8 | Jun 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04446130 | Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients | unknown | Phase 3 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | completed | Phase 3 | 365 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 18, 2020 | clinicaltrials |
| NCT00513747 | Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 84 | Alliance for Clinical Trials in OncologyOTHER | 2 | Apr 22, 2020 | clinicaltrials |
| NCT00219739 | STI571 ProspectIve RandomIzed Trial: SPIRIT(SPIRIT) | completed | Phase 3 | 789 | Poitiers University HospitalOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT02319135 | Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(FLUGAZA) | completed | Phase 3 | 289 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00003687 | Treatment for Chronic Pain in Patients With Advanced Cancer | completed | Phase 3 | 87 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma(UFT RT Phase 3) | terminated | Phase 3 | 219 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY | 18 | Mar 10, 2020 | clinicaltrials |
| NCT03793517 | Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT | recruiting | Phase 2 / Phase 3 | 55 | Peking University People's HospitalOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00707083 | Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 2,231 | Prince of Wales Hospital, Shatin, Hong KongOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02870777 | MRD-directed Therapy for Low-risk and Intermediate-risk AML. | completed | Phase 2 / Phase 3 | 743 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT02671708 | IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT | completed | Phase 2 / Phase 3 | 153 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02801578 | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT00262782 | Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 877 | German CLL Study GroupOTHER | 2 | Feb 20, 2020 | clinicaltrials |
| NCT02059720 | Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 | unknown | Phase 3 | 212 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations(AML18) | unknown | Phase 2 / Phase 3 | 1,600 | Cardiff UniversityOTHER | 2 | Jan 23, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04228393 | The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China | unknown | Phase 2 / Phase 3 | 82 | Wei ZhaoOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01118234 | Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) | completed | Phase 3 | 256 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Jan 9, 2020 | clinicaltrials |
| NCT00006451 | Bone Marrow Transplantation in Treating Patients With Leukemia | withdrawn | Phase 3 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT04216771 | Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | unknown | Phase 2 / Phase 3 | 320 | Fujian Medical UniversityOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years(DECLINE) | terminated | Phase 3 | 14 | Prof. Dr. Nikolas von BubnoffOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | terminated | Phase 3 | 58 | Stanford UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 31, 2020source: clinicaltrials